AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original): A crystalline Form I of (S)-citalopram oxalate, characterized by an x-ray powder diffraction pattern having peaks expressed as 2θ at about 6.9, 8.9, 10.8, 13.4, 14.0, 16.3, 17.6, 18.6, 19.1, 19.5, 21.2, 22.8, 23.1, 24.2, 24.5, 25.3, 27.3 degrees.

2. (Original): A crystalline Form I of (S)-citalopram oxalate as defined in claim 1, further characterized by an x-ray powder diffraction pattern as in FIG. 1.

3. (Currently Amended): A process for preparation of Form I of (S)-citalopram oxalate as defined in claim 1, which comprises: a) mixing (S)-citalopram oxalate and a suitable solvent; and b) isolating Form I of (S)-citalopram oxalate; wherein the suitable solvent is selected from the group consisting of ~~acetone,~~ ethyl acetate, methyl tert-butyl ether and acetonitrile.

4. (Currently Amended): A process according to claim 3, wherein the suitable solvent is ~~acetone~~ methyl tert-butyl ether.

5. (Original): A process according to claim 3, wherein the suitable solvent is ethyl acetate.

6. (Currently Amended): A process for preparation of Form I of (S)-citalopram oxalate as defined in claim 1, which comprises: a) adding oxalic acid to a solution of (S)-citalopram in a suitable solvent; b) isolating Form I of (S)-citalopram oxalate; wherein the suitable solvent is selected from the group consisting of ~~acetone,~~ ethyl acetate, methyl tert-butyl ether and acetonitrile.

7. (Currently Amended): A process according to claim 6, wherein the suitable solvent is ~~acetone~~ methyl tert-butyl ether.

8. (Original): A crystalline Form II of (S)-citalopram oxalate, characterized by an x-ray powder diffraction pattern having peaks expressed as 2θ at about 6.6, 10.0, 11.0, 11.9, 15.2, 16.8, 17.8, 20.3, 21.1, 21.4, 22.6, 23.0, 26.4, 28.4 degrees.

9. (Original): A crystalline Form II of (S)-citalopram oxalate as defined in claim 8, characterized by an x-ray powder diffraction pattern as in FIG. 2.

10. (Currently Amended): A process for preparation of Form II of (S)-citalopram oxalate as defined in claim 8, which comprises: a) mixing (S)-citalopram oxalate and an alcoholic solvent; b) isolating Form II of (S)-citalopram oxalate; wherein the alcoholic solvent is selected from the group consisting of methanol~~, ethanol~~ and isopropyl alcohol.

11. (Original): A process according to claim 10, wherein the alcoholic solvent is methanol.

12. (Original): A process according to claim 11, wherein Form II of (S)-citalopram oxalate is isolated by using diisopropyl ether as an anti-solvent.

13. (Currently Amended): A process for preparation of Form II of (S)-citalopram oxalate as defined in claim 8, which comprises: a) adding oxalic acid to a solution of (S)-citalopram in an alcoholic solvent; b) isolating Form II of (S)-citalopram oxalate; wherein the alcoholic solvent is selected from the group consisting of methanol~~, ethanol~~ and isopropyl alcohol.

14. (Original): A process according to claim 13, wherein the alcoholic solvent is methanol.

15. (Currently Amended): A pharmaceutical composition comprising the stable crystalline Form I of (S)-citalopram oxalate as defined in claim 1 and a pharmaceutically acceptable carrier.

16. (Currently Amended): A pharmaceutical composition comprising the stable crystalline Form II of (S)-citalopram oxalate as defined in claim 8 and a pharmaceutically acceptable carrier.